COVID19:

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus strain that causes coronavirus disease 2019 (COVID-19), a respiratory illness.

Respiratory distress syndrome is a condition in which fluid collects in the air sacs of the lungs, depriving organs of oxygen. SAR CoV 2primarily infects and deteriorates Respiratory tract and lung tree. 2019 (COVID-19), a respiratory illness.

Once the virus has got into the pneumonic state in the lungs, it can start causing problems in the air sacs in the blood vessels in your lungs - commonly wrapped around the almost broccoli shaped organs in the lungs, called the alveoli.

AOCE-05 & AOCE-06

Aodh’s lead drug-device product, AOCE-05 &AOCE-06, is a first-in-class inhaled formulation intended for SARS-CoV-2, the reported severe acute respiratory distress syndrome, a respiratory failure characterized by rapid onset of widespread inflammation in the lungs.

In recognition of the severity of SARS CoV2 acute and chronic morbidity, Aodh Lifesciences developed AOCV-05 & AOCV-06 as a treatment for patients with acute respiratory distress syndrome to relieve breathlessness and fatigue and improve exercise capacity resulting from virus infections.

Aodh’s lead drug-device product, AOCE-05 &AOCE-06, is a first-in-class inhaled formulation intended for SARS-CoV-2, the reported severe acute respiratory distress syndrome, a respiratory failure characterized by rapid onset of widespread inflammation in the lungs.

Our novel dry powder inhalation product and suspension for nebulization of AOCE-05 & AOCE-06 demonstrated excellent safety margins and was well tolerated with pharmacokinetic profiles consistent with expectations for SARS-CoV-2 medication.

Regulatroy Pathway:

  • 505(b)(2)
  • CPAT - Coronavirus Treatment Acceleration Program (CTAP)
  • Limited Population Pathway for Antibacterial and Antifungal Drugs